Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Complex Generics May Be Part Of White House Drug Pricing Response

Executive Summary

Document that appears to be fueling upcoming executive order includes ideas for relaxing FDA standards for complex generic approval, which may be one way of creating pressure to lower prices.


Related Content

US FDA Looks To Proactively Update Old Generic Drug Labels Under Pilot
Trump Administration's Pharma-Friendly Pricing Proposals Prompt Pushback
Drug Pricing 'Deeper Dive' Planned By Senate Cmte. As Industry Avoids First Blood
FDA User Fee Bill: House Cmte. Makes Technical Changes, Adds Pricing Resolution
Generic Combination Products May Be Permitted Delivery Device Variations
Generic Priority Review Expanded In Senate User Fee Bill
Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals
ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit
Complex ANDAs To Be Allowed Pre-Submission Product Meetings
Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts